drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00281 | DB00994 | 608 | 361 | [
"DDInter1066",
"DDInter1277"
] | Lidocaine | Neomycin | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Minor | 0 | [
[
[
608,
23,
361
]
],
[
[
608,
21,
28722
],
[
28722,
60,
361
]
],
[
[
608,
24,
699
],
[
699,
62,
361
]
],
[
[
608,
23,
1132
],
[
1132,
... | [
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Neomycin"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (C... | Lidocaine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Neomycin (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a minor interaction that can limit clinical effects when taken with Neomycin
Lidocaine may ca... |
DB01165 | DB05812 | 1,539 | 1,374 | [
"DDInter1325",
"DDInter8"
] | Ofloxacin | Abiraterone | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1539,
24,
1374
]
],
[
[
1539,
6,
10417
],
[
10417,
45,
1374
]
],
[
[
1539,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
1539,
62,
112
],
[
... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Ofloxacin",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
... | Ofloxacin (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Abiraterone (Compound)
Ofloxacin (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and ... |
DB00087 | DB00518 | 599 | 510 | [
"DDInter41",
"DDInter35"
] | Alemtuzumab | Albendazole | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Moderate | 1 | [
[
[
599,
24,
510
]
],
[
[
599,
24,
1220
],
[
1220,
62,
510
]
],
[
[
599,
24,
1236
],
[
1236,
63,
510
]
],
[
[
599,
24,
1101
],
[
1101,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albendazole"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Albendazole
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine ... |
DB00047 | DB01155 | 176 | 872 | [
"DDInter932",
"DDInter813"
] | Insulin glargine | Gemifloxacin | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Major | 2 | [
[
[
176,
25,
872
]
],
[
[
176,
25,
739
],
[
739,
1,
872
]
],
[
[
176,
25,
945
],
[
945,
40,
872
]
],
[
[
176,
24,
1450
],
[
1450,
63... | [
[
[
"Insulin glargine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Insulin glargine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxa... | Insulin glargine may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Insulin glargine may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin (Compound)
Insuli... |
DB06717 | DB09054 | 875 | 384 | [
"DDInter778",
"DDInter905"
] | Fosaprepitant | Idelalisib | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
875,
24,
384
]
],
[
[
875,
62,
222
],
[
222,
23,
384
]
],
[
[
875,
24,
1618
],
[
1618,
24,
384
]
],
[
[
875,
63,
891
],
[
891,
2... | [
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Fosaprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
... | Fosaprepitant may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and ... |
DB00041 | DB01004 | 1,648 | 563 | [
"DDInter38",
"DDInter806"
] | Aldesleukin | Ganciclovir | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
1648,
24,
563
]
],
[
[
1648,
24,
248
],
[
248,
40,
563
]
],
[
[
1648,
24,
552
],
[
552,
24,
563
]
],
[
[
1648,
25,
770
],
[
770,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction... |
DB06699 | DB08864 | 774 | 786 | [
"DDInter493",
"DDInter1595"
] | Degarelix | Rilpivirine | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
774,
24,
786
]
],
[
[
774,
21,
28734
],
[
28734,
60,
786
]
],
[
[
774,
62,
112
],
[
112,
23,
786
]
],
[
[
774,
63,
594
],
[
594,
... | [
[
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Degarelix",
"{u} (Compound) causes {v} (Side Effect)",
"Immune system disorder"
],
[
"Immune system disorder",
"... | Degarelix (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Rilpivirine (Compound)
Degarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effe... |
DB00761 | DB00804 | 1,621 | 1,507 | [
"DDInter1497",
"DDInter543"
] | Potassium chloride | Dicyclomine | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Major | 2 | [
[
[
1621,
25,
1507
]
],
[
[
1621,
21,
29601
],
[
29601,
60,
1507
]
],
[
[
1621,
64,
1302
],
[
1302,
24,
1507
]
],
[
[
1621,
25,
832
],
[
8... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dicyclomine"
]
],
[
[
"Potassium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Necrosis"
],
[
"Necrosis",
"{u} (Side Effect) is caus... | Potassium chloride (Compound) causes Necrosis (Side Effect) and Necrosis (Side Effect) is caused by Dicyclomine (Compound)
Potassium chloride may lead to a major life threatening interaction when taken with Protriptyline and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with D... |
DB00687 | DB08880 | 870 | 1,510 | [
"DDInter747",
"DDInter1771"
] | Fludrocortisone | Teriflunomide | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
870,
25,
1510
]
],
[
[
870,
24,
129
],
[
129,
63,
1510
]
],
[
[
870,
24,
1136
],
[
1136,
24,
1510
]
],
[
[
870,
1,
303
],
[
303,
... | [
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Deno... |
DB01206 | DB01208 | 37 | 945 | [
"DDInter1086",
"DDInter1705"
] | Lomustine | Sparfloxacin | An alkylating agent of value against both hematologic malignancies and solid tumors. | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Minor | 0 | [
[
[
37,
23,
945
]
],
[
[
37,
62,
739
],
[
739,
1,
945
]
],
[
[
37,
21,
28822
],
[
28822,
60,
945
]
],
[
[
37,
63,
1686
],
[
1686,
23... | [
[
[
"Lomustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Lomustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Lomustine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Lomustine (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Sparfloxacin (Compound)
Lomustine may cause a moderate interaction... |
DB00008 | DB00023 | 491 | 305 | [
"DDInter1407",
"DDInter127"
] | Peginterferon alfa-2a | Asparaginase Escherichia coli | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Moderate | 1 | [
[
[
491,
24,
305
]
],
[
[
491,
24,
14
],
[
14,
63,
305
]
],
[
[
491,
24,
1451
],
[
1451,
24,
305
]
],
[
[
491,
25,
876
],
[
876,
63,... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate d... |
DB00420 | DB01001 | 508 | 688 | [
"DDInter1532",
"DDInter1632"
] | Promazine | Salbutamol | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
508,
24,
688
]
],
[
[
508,
24,
874
],
[
874,
24,
688
]
],
[
[
508,
24,
1148
],
[
1148,
63,
688
]
],
[
[
508,
6,
8374
],
[
8374,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isop... |
DB00519 | DB09054 | 1,638 | 384 | [
"DDInter1843",
"DDInter905"
] | Trandolapril | Idelalisib | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1638,
24,
384
]
],
[
[
1638,
63,
305
],
[
305,
24,
384
]
],
[
[
1638,
24,
891
],
[
891,
24,
384
]
],
[
[
1638,
1,
743
],
[
743,
... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichi... | Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Trandolapril may cause a moderate interaction that could exacerbate dise... |
DB00761 | DB04843 | 1,621 | 1,511 | [
"DDInter1497",
"DDInter1149"
] | Potassium chloride | Mepenzolate | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Major | 2 | [
[
[
1621,
25,
1511
]
],
[
[
1621,
25,
537
],
[
537,
24,
1511
]
],
[
[
1621,
64,
194
],
[
194,
24,
1511
]
],
[
[
1621,
21,
28722
],
[
28722... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mepenzolate"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclizine"
],
[
"Cyclizine... | Potassium chloride may lead to a major life threatening interaction when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Potassium chloride may lead to a major life threatening interaction when taken with Darifenacin and Darifenacin may caus... |
DB00747 | DB01227 | 1,442 | 1,301 | [
"DDInter1647",
"DDInter1043"
] | Scopolamine | Levacetylmethadol | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Moderate | 1 | [
[
[
1442,
24,
1301
]
],
[
[
1442,
63,
494
],
[
494,
1,
1301
]
],
[
[
1442,
64,
675
],
[
675,
1,
1301
]
],
[
[
1442,
24,
1511
],
[
1511,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Scopolamine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Levacety... |
DB00655 | DB01259 | 559 | 392 | [
"DDInter682",
"DDInter1024"
] | Estrone | Lapatinib | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
559,
24,
392
]
],
[
[
559,
10,
11579
],
[
11579,
44,
392
]
],
[
[
559,
6,
4973
],
[
4973,
45,
392
]
],
[
[
559,
18,
10375
],
[
10375,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Estrone",
"{u} (Compound) palliates {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is treated ... | Estrone (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Estrone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Estrone (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Lapatinib (Compound)
Estrone (C... |
DB00208 | DB09075 | 1,018 | 498 | [
"DDInter1804",
"DDInter621"
] | Ticlopidine | Edoxaban | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
1018,
25,
498
]
],
[
[
1018,
23,
944
],
[
944,
62,
498
]
],
[
[
1018,
24,
41
],
[
41,
24,
498
]
],
[
[
1018,
63,
940
],
[
940,
2... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Edoxaban
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomil... |
DB00444 | DB06168 | 63 | 1,531 | [
"DDInter1765",
"DDInter281"
] | Teniposide | Canakinumab | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
63,
24,
1531
]
],
[
[
63,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
63,
24,
1270
],
[
1270,
63,
1531
]
],
[
[
63,
24,
1213
],
[
1213,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified prot... |
DB00401 | DB08899 | 84 | 129 | [
"DDInter1298",
"DDInter649"
] | Nisoldipine | Enzalutamide | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
84,
25,
129
]
],
[
[
84,
6,
8374
],
[
8374,
45,
129
]
],
[
[
84,
21,
28703
],
[
28703,
60,
129
]
],
[
[
84,
24,
1512
],
[
1512,
... | [
[
[
"Nisoldipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nisoldipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enz... | Nisoldipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Nisoldipine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and... |
DB00650 | DB00776 | 1,147 | 1,335 | [
"DDInter1041",
"DDInter1360"
] | Leucovorin | Oxcarbazepine | Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharma... | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
1147,
24,
1335
]
],
[
[
1147,
63,
1236
],
[
1236,
1,
1335
]
],
[
[
1147,
21,
28789
],
[
28789,
60,
1335
]
],
[
[
1147,
40,
356
],
[
35... | [
[
[
"Leucovorin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Leucovorin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
... | Leucovorin may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Oxcarbazepine (Compound)
Leucovorin (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Oxcarbazepine (Compound)
Leucovor... |
DB01254 | DB04574 | 1,213 | 177 | [
"DDInter484",
"DDInter684"
] | Dasatinib | Estrone sulfate (topical) | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Estrone 3-sulfate is a steroid sulfate that is the 3-sulfate of estrone. It has a role as a human metabolite and a mouse metabolite. It is a 17-oxo steroid and a steroid sulfate. It is functionally related to an estrone. It is a conjugate acid of an estrone 3-sulfate(1-). It derives from a hydride of an estrane. | Moderate | 1 | [
[
[
1213,
24,
177
]
],
[
[
1213,
63,
380
],
[
380,
1,
177
]
],
[
[
1213,
24,
35
],
[
35,
1,
177
]
],
[
[
1213,
6,
7950
],
[
7950,
45... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone sulfate"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Estrone sulfate (Compound)
Dasatinib may cause a moderate... |
DB01208 | DB09020 | 945 | 28 | [
"DDInter1705",
"DDInter212"
] | Sparfloxacin | Bisacodyl | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
945,
24,
28
]
],
[
[
945,
18,
3833
],
[
3833,
46,
28
]
],
[
[
945,
18,
2183
],
[
2183,
57,
28
]
],
[
[
945,
7,
12149
],
[
12149,
... | [
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) downregulates {v} (Gene)",
"JMJD6"
],
[
"JMJD6",
"{u} (Gene) is upregulated by {... | Sparfloxacin (Compound) downregulates JMJD6 (Gene) and JMJD6 (Gene) is upregulated by Bisacodyl (Compound)
Sparfloxacin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Bisacodyl (Compound)
Sparfloxacin (Compound) upregulates WRB (Gene) and WRB (Gene) is downregulated by Bisacodyl (Compound)
S... |
DB01232 | DB12130 | 1,327 | 1,017 | [
"DDInter1640",
"DDInter1094"
] | Saquinavir | Lorlatinib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
1327,
25,
1017
]
],
[
[
1327,
64,
608
],
[
608,
23,
1017
]
],
[
[
1327,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1327,
63,
590
],
[
590,
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may... | Saquinavir may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a mi... |
DB06206 | DB11095 | 1,268 | 235 | [
"DDInter1719",
"DDInter505"
] | Sugammadex | Desirudin | Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general ane... | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Moderate | 1 | [
[
[
1268,
24,
235
]
],
[
[
1268,
24,
1409
],
[
1409,
25,
235
]
],
[
[
1268,
24,
1421
],
[
1421,
64,
235
]
],
[
[
1268,
63,
1578
],
[
1578,... | [
[
[
"Sugammadex",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Sugammadex",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
... | Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Desirudin
Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may lead to a m... |
DB01193 | DB06792 | 819 | 1,606 | [
"DDInter12",
"DDInter1023"
] | Acebutolol | Lanthanum carbonate | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led... | Moderate | 1 | [
[
[
819,
24,
1606
]
],
[
[
819,
40,
88
],
[
88,
24,
1606
]
],
[
[
819,
62,
1152
],
[
1152,
24,
1606
]
],
[
[
819,
40,
88
],
[
88,
23... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause ... | Acebutolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Acebutolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction... |
DB00468 | DB00476 | 1,424 | 109 | [
"DDInter1557",
"DDInter608"
] | Quinine | Duloxetine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Moderate | 1 | [
[
[
1424,
24,
109
]
],
[
[
1424,
63,
847
],
[
847,
1,
109
]
],
[
[
1424,
24,
758
],
[
758,
1,
109
]
],
[
[
1424,
6,
7950
],
[
7950,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
"... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Duloxetine (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Duloxetine (Compound)
Quin... |
DB12941 | DB14723 | 466 | 159 | [
"DDInter481",
"DDInter1026"
] | Darolutamide | Larotrectinib | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Minor | 0 | [
[
[
466,
23,
159
]
],
[
[
466,
63,
907
],
[
907,
23,
159
]
],
[
[
466,
63,
98
],
[
98,
24,
159
]
],
[
[
466,
62,
597
],
[
597,
24,
... | [
[
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
... | Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Som... |
DB00661 | DB08884 | 122 | 796 | [
"DDInter1928",
"DDInter800"
] | Verapamil | Gadoxetic acid | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Gadoxetic acid (gadoxetate) is a paramagnetic gadolinium-containing ionic linear contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection. Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up ... | Moderate | 1 | [
[
[
122,
24,
796
]
],
[
[
122,
6,
9320
],
[
9320,
45,
796
]
],
[
[
122,
21,
28841
],
[
28841,
60,
796
]
],
[
[
122,
6,
16319
],
[
16319,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoxetic acid"
]
],
[
[
"Verapamil",
"{u} (Compound) binds {v} (Gene)",
"ABCC4"
],
[
"ABCC4",
"{u} (Gene) is bound by {v} (Compound)",... | Verapamil (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Gadoxetic acid (Compound)
Verapamil (Compound) causes Bronchospasm (Side Effect) and Bronchospasm (Side Effect) is caused by Gadoxetic acid (Compound)
Verapamil (Compound) binds ABCC3 (Gene) and ABCC3 (Gene) is bound by Nifedipine (Compound) and Nifed... |
DB00539 | DB11986 | 11 | 484 | [
"DDInter1837",
"DDInter648"
] | Toremifene | Entrectinib | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
11,
25,
484
]
],
[
[
11,
23,
1247
],
[
1247,
23,
484
]
],
[
[
11,
25,
1539
],
[
1539,
24,
484
]
],
[
[
11,
24,
998
],
[
998,
24,... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfa... | Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Toremifene may lead to a major life threatening interaction when taken with Ofloxacin and Ofloxacin may... |
DB00595 | DB14520 | 1,545 | 1,229 | [
"DDInter1374",
"DDInter1785"
] | Oxytetracycline | Tetraferric tricitrate decahydrate | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Moderate | 1 | [
[
[
1545,
24,
1229
]
],
[
[
1545,
24,
955
],
[
955,
23,
1229
]
],
[
[
1545,
24,
954
],
[
954,
24,
1229
]
],
[
[
1545,
40,
1669
],
[
1669,
... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Oxytetracycline may cause a moderate interaction that could exa... |
DB01261 | DB11732 | 170 | 1,097 | [
"DDInter1679",
"DDInter1027"
] | Sitagliptin | Lasmiditan | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
170,
24,
1097
]
],
[
[
170,
24,
850
],
[
850,
24,
1097
]
],
[
[
170,
63,
999
],
[
999,
24,
1097
]
],
[
[
170,
24,
1033
],
[
1033,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with T... |
DB01114 | DB01175 | 272 | 318 | [
"DDInter362",
"DDInter672"
] | Chlorpheniramine | Escitalopram | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
272,
24,
318
]
],
[
[
272,
63,
1230
],
[
1230,
1,
318
]
],
[
[
272,
6,
8374
],
[
8374,
45,
318
]
],
[
[
272,
18,
3741
],
[
3741,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Chlorpheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Chlorpheniramine (Compound) downregulates OXA1L (G... |
DB00569 | DB00991 | 553 | 97 | [
"DDInter775",
"DDInter1358"
] | Fondaparinux | Oxaprozin | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Major | 2 | [
[
[
553,
25,
97
]
],
[
[
553,
25,
1274
],
[
1274,
24,
97
]
],
[
[
553,
25,
998
],
[
998,
1,
97
]
],
[
[
553,
21,
29017
],
[
29017,
6... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaprozin"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
... | Fondaparinux may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Fondaparinux may lead to a major life threatening interaction when taken with Phenylbutazone and Phenylbutazone (Compound)... |
DB01128 | DB11718 | 918 | 927 | [
"DDInter204",
"DDInter640"
] | Bicalutamide | Encorafenib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
918,
24,
927
]
],
[
[
918,
62,
112
],
[
112,
23,
927
]
],
[
[
918,
24,
720
],
[
720,
24,
927
]
],
[
[
918,
63,
216
],
[
216,
24,... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil an... |
DB04946 | DB09098 | 924 | 98 | [
"DDInter907",
"DDInter1700"
] | Iloperidone | Somatrem | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
924,
24,
98
]
],
[
[
924,
24,
159
],
[
159,
63,
98
]
],
[
[
924,
64,
11
],
[
11,
24,
98
]
],
[
[
924,
63,
1647
],
[
1647,
24,
... | [
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[... | Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Iloperidone may lead to a major life threatening interaction when taken with Toremifene and Toremifene may ... |
DB00531 | DB10989 | 450 | 496 | [
"DDInter456",
"DDInter858"
] | Cyclophosphamide | Hepatitis A Vaccine | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
450,
24,
496
]
],
[
[
450,
24,
4
],
[
4,
24,
496
]
],
[
[
450,
24,
738
],
[
738,
63,
496
]
],
[
[
450,
25,
976
],
[
976,
24,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacet... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Cyclophosphamide may cause a moderate interaction that could exacer... |
DB00777 | DB08824 | 146 | 591 | [
"DDInter1537",
"DDInter959"
] | Propiomazine | Ioflupane I-123 | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
146,
24,
591
]
],
[
[
146,
40,
684
],
[
684,
24,
591
]
],
[
[
146,
24,
401
],
[
401,
24,
591
]
],
[
[
146,
1,
104
],
[
104,
24,
... | [
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Propiomazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
],
[
"Thioridazine",
"{u} may ca... | Propiomazine (Compound) resembles Thioridazine (Compound) and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate inter... |
DB01209 | DB08895 | 1,359 | 976 | [
"DDInter531",
"DDInter1825"
] | Dezocine | Tofacitinib | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
1359,
24,
976
]
],
[
[
1359,
25,
407
],
[
407,
63,
976
]
],
[
[
1359,
64,
475
],
[
475,
24,
976
]
],
[
[
1359,
40,
234
],
[
234,
... | [
[
[
"Dezocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dezocine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opium",
"{u}... | Dezocine may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dezocine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that coul... |
DB00563 | DB00586 | 663 | 1,512 | [
"DDInter1174",
"DDInter537"
] | Methotrexate | Diclofenac | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Major | 2 | [
[
[
663,
25,
1512
]
],
[
[
663,
25,
1263
],
[
1263,
63,
1512
]
],
[
[
663,
6,
9320
],
[
9320,
45,
1512
]
],
[
[
663,
7,
7720
],
[
7720,
... | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bromfenac"
],
[
"Bromfenac",
"{u}... | Methotrexate may lead to a major life threatening interaction when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Methotrexate (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Diclofenac (Compound)
Methotrexate (Compound) upregulat... |
DB00407 | DB00945 | 202 | 1,479 | [
"DDInter115",
"DDInter20"
] | Ardeparin | Acetylsalicylic acid | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Major | 2 | [
[
[
202,
25,
1479
]
],
[
[
202,
21,
28931
],
[
28931,
60,
1479
]
],
[
[
202,
24,
557
],
[
557,
63,
1479
]
],
[
[
202,
25,
714
],
[
714,
... | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Ardeparin",
"{u} (Compound) causes {v} (Side Effect)",
"Haemorrhage"
],
[
"Haemorrhage",
"{u} (Side Effect) is caused ... | Ardeparin (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Acetylsalicylic acid (Compound)
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases... |
DB08908 | DB13985 | 713 | 546 | [
"DDInter564",
"DDInter1108"
] | Dimethyl fumarate | Lutetium Lu 177 dotatate | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Moderate | 1 | [
[
[
713,
24,
546
]
],
[
[
713,
63,
66
],
[
66,
24,
546
]
],
[
[
713,
24,
1613
],
[
1613,
24,
546
]
],
[
[
713,
64,
1057
],
[
1057,
2... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when take... |
DB01169 | DB11796 | 57 | 1,612 | [
"DDInter120",
"DDInter786"
] | Arsenic trioxide | Fostemsavir | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Major | 2 | [
[
[
57,
25,
1612
]
],
[
[
57,
62,
112
],
[
112,
23,
1612
]
],
[
[
57,
64,
1424
],
[
1424,
24,
1612
]
],
[
[
57,
25,
823
],
[
823,
63... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Arsenic trioxide may lead to a major life threatening interaction when taken with Quinine and Quinine m... |
DB00618 | DB01053 | 1,572 | 514 | [
"DDInter498",
"DDInter189"
] | Demeclocycline | Benzylpenicillin | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible o... | Moderate | 1 | [
[
[
1572,
24,
514
]
],
[
[
1572,
24,
1390
],
[
1390,
1,
514
]
],
[
[
1572,
24,
1681
],
[
1681,
40,
514
]
],
[
[
1572,
63,
703
],
[
703,
... | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzylpenicillin"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticarcillin"
... | Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Ticarcillin and Ticarcillin (Compound) resembles Benzylpenicillin (Compound)
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Mezlocillin and Mezlocillin (Compound) resembles Benz... |
DB01017 | DB01377 | 1,669 | 1,283 | [
"DDInter1224",
"DDInter1119"
] | Minocycline | Magnesium oxide | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Moderate | 1 | [
[
[
1669,
24,
1283
]
],
[
[
1669,
63,
1252
],
[
1252,
23,
1283
]
],
[
[
1669,
24,
1482
],
[
1482,
62,
1283
]
],
[
[
1669,
24,
339
],
[
339... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
... | Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxi... |
DB00030 | DB00575 | 1,685 | 1,020 | [
"DDInter934",
"DDInter412"
] | Insulin human | Clonidine | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Moderate | 1 | [
[
[
1685,
24,
1020
]
],
[
[
1685,
24,
433
],
[
433,
63,
1020
]
],
[
[
1685,
24,
245
],
[
245,
24,
1020
]
],
[
[
1685,
23,
274
],
[
274,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Clonidine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Glimepirid... |
DB00280 | DB08868 | 494 | 1,011 | [
"DDInter575",
"DDInter737"
] | Disopyramide | Fingolimod | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
494,
25,
1011
]
],
[
[
494,
6,
8374
],
[
8374,
45,
1011
]
],
[
[
494,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
494,
23,
112
],
[
112,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fin... | Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Disopyramide (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Metro... |
DB00615 | DB11995 | 690 | 1,634 | [
"DDInter1589",
"DDInter143"
] | Rifabutin | Avatrombopag | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require pla... | Moderate | 1 | [
[
[
690,
24,
1634
]
],
[
[
690,
25,
760
],
[
760,
24,
1634
]
],
[
[
690,
24,
609
],
[
609,
24,
1634
]
],
[
[
690,
63,
254
],
[
254,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat... | Rifabutin may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin ma... |
DB00024 | DB01309 | 818 | 1,254 | [
"DDInter1800",
"DDInter933"
] | Thyrotropin alfa | Insulin glulisine | Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cance... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
818,
24,
1254
]
],
[
[
818,
24,
1645
],
[
1645,
24,
1254
]
],
[
[
818,
24,
1450
],
[
1450,
63,
1254
]
],
[
[
818,
24,
1645
],
[
1645,
... | [
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformi... | Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Empa... |
DB00691 | DB00860 | 1,058 | 891 | [
"DDInter1237",
"DDInter1513"
] | Moexipril | Prednisolone | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1058,
24,
891
]
],
[
[
1058,
63,
175
],
[
175,
40,
891
]
],
[
[
1058,
24,
167
],
[
167,
1,
891
]
],
[
[
1058,
24,
617
],
[
617,
... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[... | Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Predniso... |
DB00365 | DB06292 | 839 | 549 | [
"DDInter842",
"DDInter474"
] | Grepafloxacin | Dapagliflozin | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
839,
24,
549
]
],
[
[
839,
24,
1344
],
[
1344,
40,
549
]
],
[
[
839,
24,
467
],
[
467,
23,
549
]
],
[
[
839,
25,
79
],
[
79,
23,... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interact... |
DB01050 | DB01115 | 848 | 336 | [
"DDInter900",
"DDInter1291"
] | Ibuprofen | Nifedipine | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Moderate | 1 | [
[
[
848,
24,
336
]
],
[
[
848,
63,
1428
],
[
1428,
1,
336
]
],
[
[
848,
63,
1081
],
[
1081,
40,
336
]
],
[
[
848,
6,
4973
],
[
4973,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedipine (Compound)
... |
DB00771 | DB00924 | 262 | 1,405 | [
"DDInter397",
"DDInter454"
] | Clidinium | Cyclobenzaprine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Moderate | 1 | [
[
[
262,
24,
1405
]
],
[
[
262,
63,
1302
],
[
1302,
1,
1405
]
],
[
[
262,
24,
358
],
[
358,
1,
1405
]
],
[
[
262,
24,
401
],
[
401,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Cyclobenzaprine (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Cyclobenz... |
DB01142 | DB09039 | 1,264 | 1,670 | [
"DDInter593",
"DDInter629"
] | Doxepin | Eliglustat | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
1264,
24,
1670
]
],
[
[
1264,
63,
479
],
[
479,
23,
1670
]
],
[
[
1264,
63,
121
],
[
121,
24,
1670
]
],
[
[
1264,
74,
1164
],
[
1164,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Do... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine m... |
DB00675 | DB04868 | 888 | 478 | [
"DDInter1744",
"DDInter1293"
] | Tamoxifen | Nilotinib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
888,
25,
478
]
],
[
[
888,
6,
6017
],
[
6017,
45,
478
]
],
[
[
888,
7,
16662
],
[
16662,
46,
478
]
],
[
[
888,
18,
2183
],
[
2183,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"... | Tamoxifen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Tamoxifen (Compound) upregulates SQRDL (Gene) and SQRDL (Gene) is upregulated by Nilotinib (Compound)
Tamoxifen (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Nilotinib (Compound)
Tamoxifen (Compound)... |
DB00214 | DB01142 | 1,028 | 1,264 | [
"DDInter1836",
"DDInter593"
] | Torasemide | Doxepin | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1028,
24,
1264
]
],
[
[
1028,
24,
401
],
[
401,
24,
1264
]
],
[
[
1028,
6,
6017
],
[
6017,
45,
1264
]
],
[
[
1028,
21,
28898
],
[
2889... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Torasemide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Doxepin (Compound)
Torasemide (Compound... |
DB00108 | DB11760 | 1,066 | 119 | [
"DDInter1268",
"DDInter1742"
] | Natalizumab | Talazoparib | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Major | 2 | [
[
[
1066,
25,
119
]
],
[
[
1066,
64,
66
],
[
66,
24,
119
]
],
[
[
1066,
24,
1129
],
[
1129,
63,
119
]
],
[
[
1066,
25,
713
],
[
713,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u... | Natalizumab may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 str... |
DB00773 | DB11732 | 896 | 1,097 | [
"DDInter702",
"DDInter1027"
] | Etoposide | Lasmiditan | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
896,
24,
1097
]
],
[
[
896,
24,
971
],
[
971,
63,
1097
]
],
[
[
896,
24,
77
],
[
77,
24,
1097
]
],
[
[
896,
64,
1064
],
[
1064,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idar... |
DB00794 | DB11921 | 759 | 1,019 | [
"DDInter1521",
"DDInter492"
] | Primidone | Deflazacort | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
759,
25,
1019
]
],
[
[
759,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
759,
24,
761
],
[
761,
24,
1019
]
],
[
[
759,
25,
629
],
[
629,
... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxaglip... |
DB00344 | DB00719 | 1,302 | 1,219 | [
"DDInter1543",
"DDInter149"
] | Protriptyline | Azatadine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
1302,
24,
1219
]
],
[
[
1302,
24,
13
],
[
13,
24,
1219
]
],
[
[
1302,
24,
830
],
[
830,
1,
1219
]
],
[
[
1302,
40,
114
],
[
114,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Pheninda... |
DB00078 | DB09030 | 1,172 | 840 | [
"DDInter898",
"DDInter1945"
] | Ibritumomab tiuxetan | Vorapaxar | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
1172,
25,
840
]
],
[
[
1172,
23,
944
],
[
944,
62,
840
]
],
[
[
1172,
24,
765
],
[
765,
24,
840
]
],
[
[
1172,
25,
885
],
[
885,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
... | Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Hemin an... |
DB00009 | DB11703 | 1,271 | 405 | [
"DDInter56",
"DDInter9"
] | Alteplase | Acalabrutinib | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1271,
25,
405
]
],
[
[
1271,
24,
383
],
[
383,
24,
405
]
],
[
[
1271,
24,
738
],
[
738,
63,
405
]
],
[
[
1271,
24,
804
],
[
804,
... | [
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00361 | DB11932 | 134 | 327 | [
"DDInter1939",
"DDInter3"
] | Vinorelbine | Abametapir (topical) | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
134,
24,
327
]
],
[
[
134,
24,
124
],
[
124,
63,
327
]
],
[
[
134,
63,
168
],
[
168,
24,
327
]
],
[
[
134,
24,
79
],
[
79,
24,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Vinorelbin... |
DB00439 | DB12267 | 289 | 1,476 | [
"DDInter341",
"DDInter233"
] | Cerivastatin | Brigatinib | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
289,
24,
1476
]
],
[
[
289,
63,
168
],
[
168,
23,
1476
]
],
[
[
289,
24,
629
],
[
629,
24,
1476
]
],
[
[
289,
25,
1668
],
[
1668,
... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirol... |
DB00674 | DB00889 | 1,516 | 1,133 | [
"DDInter802",
"DDInter840"
] | Galantamine | Granisetron | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
1516,
24,
1133
]
],
[
[
1516,
63,
19
],
[
19,
40,
1133
]
],
[
[
1516,
63,
85
],
[
85,
1,
1133
]
],
[
[
1516,
6,
8374
],
[
8374,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Granisetron (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Granisetron (Compound... |
DB00308 | DB06589 | 347 | 1,250 | [
"DDInter901",
"DDInter1400"
] | Ibutilide | Pazopanib | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
347,
25,
1250
]
],
[
[
347,
21,
29170
],
[
29170,
60,
1250
]
],
[
[
347,
23,
112
],
[
112,
23,
1250
]
],
[
[
347,
25,
1151
],
[
1151,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Ibutilide",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac failure congestive"
],
[
"Cardiac failure congestive",
"{u} (Side... | Ibutilide (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Pazopanib (Compound)
Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinica... |
DB06210 | DB09481 | 72 | 460 | [
"DDInter631",
"DDInter1113"
] | Eltrombopag | Magnesium carbonate | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
72,
24,
460
]
],
[
[
72,
63,
14
],
[
14,
24,
460
]
],
[
[
72,
24,
853
],
[
853,
24,
460
]
],
[
[
72,
24,
260
],
[
260,
63,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Magnes... |
DB04938 | DB09054 | 1,423 | 384 | [
"DDInter1353",
"DDInter905"
] | Ospemifene | Idelalisib | Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1423,
24,
384
]
],
[
[
1423,
24,
72
],
[
72,
24,
384
]
],
[
[
1423,
74,
888
],
[
888,
24,
384
]
],
[
[
1423,
64,
600
],
[
600,
2... | [
[
[
"Ospemifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ospemifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
[
... | Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ospemifene (Compound) resembles Tamoxifen (Compound) and Ospemifene may cause a moderate interaction that coul... |
DB00312 | DB00398 | 1,023 | 79 | [
"DDInter1423",
"DDInter1702"
] | Pentobarbital | Sorafenib | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Moderate | 1 | [
[
[
1023,
24,
79
]
],
[
[
1023,
6,
10215
],
[
10215,
45,
79
]
],
[
[
1023,
18,
18226
],
[
18226,
46,
79
]
],
[
[
1023,
7,
2940
],
[
2940,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Comp... | Pentobarbital (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Sorafenib (Compound)
Pentobarbital (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is upregulated by Sorafenib (Compound)
Pentobarbital (Compound) upregulates BUB1B (Gene) and BUB1B (Gene) is downregulated by Sorafenib (Compound)
Pentob... |
DB01259 | DB13139 | 392 | 1,032 | [
"DDInter1024",
"DDInter1063"
] | Lapatinib | Levosalbutamol | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
392,
24,
1032
]
],
[
[
392,
63,
1573
],
[
1573,
23,
1032
]
],
[
[
392,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
392,
24,
124
],
[
124,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Lapatinib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may ca... |
DB00515 | DB12865 | 589 | 922 | [
"DDInter387",
"DDInter688"
] | Cisplatin | Etelcalcetide | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. | Major | 2 | [
[
[
589,
25,
922
]
],
[
[
589,
63,
1028
],
[
1028,
25,
922
]
],
[
[
589,
24,
1136
],
[
1136,
25,
922
]
],
[
[
589,
63,
1028
],
[
1028,
... | [
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etelcalcetide"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Torasemide"
],
[
"Torasemid... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may lead to a major life threatening interaction when taken with Etelcalcetide
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may lead to... |
DB00741 | DB09104 | 167 | 286 | [
"DDInter885",
"DDInter1118"
] | Hydrocortisone | Magnesium hydroxide | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
167,
24,
286
]
],
[
[
167,
24,
1482
],
[
1482,
23,
286
]
],
[
[
167,
63,
88
],
[
88,
23,
286
]
],
[
[
167,
62,
1018
],
[
1018,
2... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Metoprol... |
DB00081 | DB11166 | 273 | 18 | [
"DDInter1838",
"DDInter104"
] | Tositumomab | Antithrombin Alfa | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Major | 2 | [
[
[
273,
25,
18
]
],
[
[
273,
25,
714
],
[
714,
24,
18
]
],
[
[
273,
24,
738
],
[
738,
63,
18
]
],
[
[
273,
37,
1274
],
[
1274,
24,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"... | Tositumomab may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cau... |
DB00694 | DB04868 | 51 | 478 | [
"DDInter485",
"DDInter1293"
] | Daunorubicin | Nilotinib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
51,
25,
478
]
],
[
[
51,
24,
1468
],
[
1468,
63,
478
]
],
[
[
51,
5,
11555
],
[
11555,
44,
478
]
],
[
[
51,
6,
4973
],
[
4973,
4... | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatini... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Daunorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Niloti... |
DB09078 | DB09330 | 1,228 | 985 | [
"DDInter1036",
"DDInter1352"
] | Lenvatinib | Osimertinib | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1228,
25,
985
]
],
[
[
1228,
62,
1247
],
[
1247,
23,
985
]
],
[
[
1228,
63,
480
],
[
480,
24,
985
]
],
[
[
1228,
24,
657
],
[
657,
... | [
[
[
"Lenvatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Lenvatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfa... | Lenvatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol a... |
DB09080 | DB14881 | 144 | 180 | [
"DDInter1331",
"DDInter1329"
] | Olodaterol | Oliceridine | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
144,
24,
180
]
],
[
[
144,
63,
401
],
[
401,
24,
180
]
],
[
[
144,
24,
124
],
[
124,
24,
180
]
],
[
[
144,
63,
702
],
[
702,
25,... | [
[
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[... | Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Gl... |
DB00196 | DB09330 | 600 | 985 | [
"DDInter743",
"DDInter1352"
] | Fluconazole | Osimertinib | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
600,
25,
985
]
],
[
[
600,
23,
1247
],
[
1247,
23,
985
]
],
[
[
600,
24,
608
],
[
608,
23,
985
]
],
[
[
600,
25,
1478
],
[
1478,
... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sul... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine ... |
DB00574 | DB06779 | 121 | 365 | [
"DDInter717",
"DDInter470"
] | Fenfluramine | Dalteparin | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Moderate | 1 | [
[
[
121,
24,
365
]
],
[
[
121,
64,
1100
],
[
1100,
24,
365
]
],
[
[
121,
25,
1427
],
[
1427,
63,
365
]
],
[
[
121,
25,
1039
],
[
1039,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venla... | Fenfluramine may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Fenfluramine may lead to a major life threatening interaction when taken with Vortioxetine and Vortioxetine may cause a mod... |
DB00022 | DB00445 | 268 | 322 | [
"DDInter1408",
"DDInter655"
] | Peginterferon alfa-2b | Epirubicin | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
268,
24,
322
]
],
[
[
268,
24,
112
],
[
112,
62,
322
]
],
[
[
268,
24,
671
],
[
671,
63,
322
]
],
[
[
268,
24,
134
],
[
134,
24,... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metro... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Epirubicin
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00704 | DB01033 | 267 | 328 | [
"DDInter1263",
"DDInter1156"
] | Naltrexone | Mercaptopurine | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Moderate | 1 | [
[
[
267,
24,
328
]
],
[
[
267,
21,
28681
],
[
28681,
60,
328
]
],
[
[
267,
63,
1299
],
[
1299,
23,
328
]
],
[
[
267,
24,
1627
],
[
1627,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Naltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Si... | Naltrexone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Mercaptopurine (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects w... |
DB01183 | DB01209 | 173 | 1,359 | [
"DDInter1262",
"DDInter531"
] | Naloxone | Dezocine | Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, ... | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
173,
24,
1359
]
],
[
[
173,
63,
234
],
[
234,
1,
1359
]
],
[
[
173,
1,
11505
],
[
11505,
1,
1359
]
],
[
[
173,
6,
7940
],
[
7940,
... | [
[
[
"Naloxone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Naloxone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
],
[
"... | Naloxone may cause a moderate interaction that could exacerbate diseases when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Naloxone (Compound) resembles Levallorphan (Compound) and Levallorphan (Compound) resembles Dezocine (Compound)
Naloxone (Compound) binds OPRK1 (Gene) and OPRK1 (... |
DB00445 | DB11988 | 322 | 270 | [
"DDInter655",
"DDInter1321"
] | Epirubicin | Ocrelizumab | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
322,
24,
270
]
],
[
[
322,
63,
1461
],
[
1461,
23,
270
]
],
[
[
322,
63,
134
],
[
134,
24,
270
]
],
[
[
322,
24,
1491
],
[
1491,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelb... |
DB00570 | DB09115 | 147 | 505 | [
"DDInter1936",
"DDInter559"
] | Vinblastine | Diiodohydroxyquinoline | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Moderate | 1 | [
[
[
147,
24,
505
]
],
[
[
147,
24,
1593
],
[
1593,
24,
505
]
],
[
[
147,
25,
908
],
[
908,
24,
505
]
],
[
[
147,
63,
168
],
[
168,
2... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Vinblastine may lead to a major life threatening interaction when taken with Golimumab and Golimuma... |
DB00342 | DB13139 | 1,181 | 1,032 | [
"DDInter1770",
"DDInter1063"
] | Terfenadine | Levosalbutamol | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1181,
24,
1032
]
],
[
[
1181,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
1181,
24,
124
],
[
124,
24,
1032
]
],
[
[
1181,
25,
982
],
[
982,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Ca... | Terfenadine may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib ma... |
DB00363 | DB00637 | 695 | 1,557 | [
"DDInter419",
"DDInter128"
] | Clozapine | Astemizole | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Major | 2 | [
[
[
695,
25,
1557
]
],
[
[
695,
6,
8374
],
[
8374,
45,
1557
]
],
[
[
695,
18,
4884
],
[
4884,
57,
1557
]
],
[
[
695,
23,
112
],
[
112,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Astemizol... | Clozapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Astemizole (Compound)
Clozapine (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Astemizole (Compound)
Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazol... |
DB00238 | DB00570 | 188 | 147 | [
"DDInter1285",
"DDInter1936"
] | Nevirapine | Vinblastine | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
188,
24,
147
]
],
[
[
188,
24,
134
],
[
134,
24,
147
]
],
[
[
188,
6,
8374
],
[
8374,
45,
147
]
],
[
[
188,
21,
29196
],
[
29196,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vinblastine (Compound)
Nevirapine (Co... |
DB00574 | DB00816 | 121 | 1,674 | [
"DDInter717",
"DDInter1346"
] | Fenfluramine | Orciprenaline | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
121,
24,
1674
]
],
[
[
121,
24,
1164
],
[
1164,
24,
1674
]
],
[
[
121,
63,
1685
],
[
1685,
24,
1674
]
],
[
[
121,
24,
959
],
[
959,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Insulin hu... |
DB01589 | DB04868 | 481 | 478 | [
"DDInter1552",
"DDInter1293"
] | Quazepam | Nilotinib | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
481,
24,
478
]
],
[
[
481,
6,
6017
],
[
6017,
45,
478
]
],
[
[
481,
21,
28762
],
[
28762,
60,
478
]
],
[
[
481,
24,
1040
],
[
1040,
... | [
[
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Quazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Quazepam (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Quazepam (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nilotinib (Compound)
Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may... |
DB00401 | DB08820 | 84 | 1,478 | [
"DDInter1298",
"DDInter997"
] | Nisoldipine | Ivacaftor | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
84,
24,
1478
]
],
[
[
84,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
84,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
84,
24,
617
],
[
617,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Nisoldipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Nisoldipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Nisoldipine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budes... |
DB08868 | DB12498 | 1,011 | 76 | [
"DDInter737",
"DDInter1238"
] | Fingolimod | Mogamulizumab | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Major | 2 | [
[
[
1011,
25,
76
]
],
[
[
1011,
64,
1531
],
[
1531,
24,
76
]
],
[
[
1011,
24,
496
],
[
496,
24,
76
]
],
[
[
1011,
24,
987
],
[
987,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"... | Fingolimod may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatit... |
DB00999 | DB01240 | 504 | 885 | [
"DDInter883",
"DDInter657"
] | Hydrochlorothiazide | Epoprostenol | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
504,
24,
885
]
],
[
[
504,
63,
1061
],
[
1061,
1,
885
]
],
[
[
504,
21,
28684
],
[
28684,
60,
885
]
],
[
[
504,
63,
1512
],
[
1512,
... | [
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trepros... | Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Hydrochlorothiazide (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Epoprostenol (Compound)
Hydrochlor... |
DB00398 | DB09472 | 79 | 1,383 | [
"DDInter1702",
"DDInter1693"
] | Sorafenib | Sodium sulfate | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
79,
24,
1383
]
],
[
[
79,
63,
1252
],
[
1252,
23,
1383
]
],
[
[
79,
24,
609
],
[
609,
24,
1383
]
],
[
[
79,
63,
521
],
[
521,
24... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithr... |
DB06228 | DB06448 | 792 | 171 | [
"DDInter1609",
"DDInter1087"
] | Rivaroxaban | Lonafarnib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Major | 2 | [
[
[
792,
25,
171
]
],
[
[
792,
63,
222
],
[
222,
23,
171
]
],
[
[
792,
64,
1347
],
[
1347,
24,
171
]
],
[
[
792,
63,
1424
],
[
1424,
... | [
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutra... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Rivaroxaban may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may ca... |
DB00631 | DB00649 | 372 | 231 | [
"DDInter405",
"DDInter1710"
] | Clofarabine | Stavudine | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Moderate | 1 | [
[
[
372,
24,
231
]
],
[
[
372,
63,
139
],
[
139,
1,
231
]
],
[
[
372,
7,
3727
],
[
3727,
46,
231
]
],
[
[
372,
21,
28810
],
[
28810,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Stavudine (Compound)
Clofarabine (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Stavudine (Compound)
Clofarabine (Compound) causes Gastrointestinal pain (Side Ef... |
DB00470 | DB01244 | 530 | 762 | [
"DDInter601",
"DDInter192"
] | Dronabinol | Bepridil | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Moderate | 1 | [
[
[
530,
24,
762
]
],
[
[
530,
24,
1376
],
[
1376,
24,
762
]
],
[
[
530,
24,
704
],
[
704,
1,
762
]
],
[
[
530,
24,
832
],
[
832,
40... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and ... |
DB00570 | DB01319 | 147 | 34 | [
"DDInter1936",
"DDInter777"
] | Vinblastine | Fosamprenavir | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Major | 2 | [
[
[
147,
25,
34
]
],
[
[
147,
25,
1091
],
[
1091,
40,
34
]
],
[
[
147,
6,
8374
],
[
8374,
45,
34
]
],
[
[
147,
21,
28661
],
[
28661,
... | [
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"... | Vinblastine may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Vinblastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Vinblastine (Compound) causes Acute coronary syndrome (Side Effect) and A... |
DB00570 | DB00631 | 147 | 372 | [
"DDInter1936",
"DDInter405"
] | Vinblastine | Clofarabine | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
147,
24,
372
]
],
[
[
147,
64,
1064
],
[
1064,
25,
372
]
],
[
[
147,
24,
1488
],
[
1488,
40,
372
]
],
[
[
147,
5,
11555
],
[
11555,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladrib... | Vinblastine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Clofarabine
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine (Compound) resembles... |
DB00570 | DB14975 | 147 | 988 | [
"DDInter1936",
"DDInter1949"
] | Vinblastine | Voxelotor | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
147,
24,
988
]
],
[
[
147,
24,
629
],
[
629,
24,
988
]
],
[
[
147,
62,
63
],
[
63,
24,
988
]
],
[
[
147,
23,
896
],
[
896,
24,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Teniposide and Teniposid... |
DB01050 | DB09413 | 848 | 1,203 | [
"DDInter900",
"DDInter1241"
] | Ibuprofen | Monopotassium phosphate | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Monopotassium phosphate, MKP, (also potassium dihydrogenphosphate, KDP, or monobasic potassium phosphate), KH2PO4, is a soluble salt of potassium and the dihydrogen phosphate ion. It is a source of phosphorus and potassium as well as a buffering agent. It can be used in fertilizer mixtures to reduce escape of ammonia b... | Moderate | 1 | [
[
[
848,
24,
1203
]
],
[
[
848,
63,
1512
],
[
1512,
24,
1203
]
],
[
[
848,
74,
1274
],
[
1274,
24,
1203
]
],
[
[
848,
63,
1512
],
[
1512,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Monopotassium phosphate"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Monopotassium phosphate
Ibuprofen (Compound) resembles Flurbiprofen (Compound) and Ibuprofen may cause a moderate interactio... |
DB00603 | DB11979 | 303 | 1,320 | [
"DDInter1137",
"DDInter625"
] | Medroxyprogesterone acetate | Elagolix | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
303,
24,
1320
]
],
[
[
303,
24,
129
],
[
129,
24,
1320
]
],
[
[
303,
24,
484
],
[
484,
63,
1320
]
],
[
[
303,
23,
888
],
[
888,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases w... |
DB11827 | DB14731 | 433 | 1,518 | [
"DDInter669",
"DDInter1741"
] | Ertugliflozin | Tagraxofusp | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
433,
24,
1518
]
],
[
[
433,
63,
176
],
[
176,
24,
1518
]
],
[
[
433,
63,
695
],
[
695,
25,
1518
]
],
[
[
433,
63,
176
],
[
176,
... | [
[
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
... | Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Cl... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.